Table 1. Description of patients with... | American Society of Hematology

Table 1.

Description of patients with primary HIV-1 infection

Patient	Treatment	Initial Viremia (RNA Copies)^*	Final Viremia (RNA Copies)^†
P1	none	216 415^‡	17 322^‡
P6	none	2 617 358^‡	65 938^‡
P8	none	1774^‡	40 963^‡
P9	none	91 390^‡	83 150^‡
P10	none	—	—
P14	none	—	—
P16	none	389 500^‡	35 450^‡
P17	none	—	—
P18	none	553 600^‡	89 860^‡
P20	none^1-153	383 620^‡	2850^‡
P24	none	—	—
101	AZT/3TC/saquinavir	7500^1-155	< 400^1-155
102	AZT/3TC/saquinavir	2 300 000^1-155	32 000^1-155
103	AZT/3TC/saquinavir	1 700 000^1-155	< 400^1-155
104	AZT/ddl	62 443^1-155	31^1-155
105	AZT/ddl	2 127 976^1-155	1 671^1-155
1155	AZT/3TC/indinavir	109 270^1-154	< 500^1-154
1168	AZT/3TC/indinavir	128 814^1-154	< 500^1-154
1188	AZT/3TC/indinavir	73 074^1-154	< 500^1-154
1166	AZT/3TC/indinavir	206 652^1-154	< 500^1-154
1192	AZT/3TC/indinavir	67 862^1-154	< 500^1-154
1196	AZT/3TC/indinavir	38 900^1-154	< 500^1-154
0407#	AZT/3TC/indinavir	15 105^1-160	< 400^1-160

Patient	Treatment	Initial Viremia (RNA Copies)^*	Final Viremia (RNA Copies)^†
P1	none	216 415^‡	17 322^‡
P6	none	2 617 358^‡	65 938^‡
P8	none	1774^‡	40 963^‡
P9	none	91 390^‡	83 150^‡
P10	none	—	—
P14	none	—	—
P16	none	389 500^‡	35 450^‡
P17	none	—	—
P18	none	553 600^‡	89 860^‡
P20	none^1-153	383 620^‡	2850^‡
P24	none	—	—
101	AZT/3TC/saquinavir	7500^1-155	< 400^1-155
102	AZT/3TC/saquinavir	2 300 000^1-155	32 000^1-155
103	AZT/3TC/saquinavir	1 700 000^1-155	< 400^1-155
104	AZT/ddl	62 443^1-155	31^1-155
105	AZT/ddl	2 127 976^1-155	1 671^1-155
1155	AZT/3TC/indinavir	109 270^1-154	< 500^1-154
1168	AZT/3TC/indinavir	128 814^1-154	< 500^1-154
1188	AZT/3TC/indinavir	73 074^1-154	< 500^1-154
1166	AZT/3TC/indinavir	206 652^1-154	< 500^1-154
1192	AZT/3TC/indinavir	67 862^1-154	< 500^1-154
1196	AZT/3TC/indinavir	38 900^1-154	< 500^1-154
0407#	AZT/3TC/indinavir	15 105^1-160	< 400^1-160

Blank cells indicate not determined.

Tested on the time point closest to clinical presentation.

Tested on the time point closest to the end of TCRBV repertoire follow-up.

Determined by means of quantitative-competitive PCR.

Treatment with AZT/3TC/ddl initiated after day 150.

Determined by means of NASBA.

Determined by means of Chiron bDNA assay.

#Not included in TCRBV repertoire follow-up.

Determined by means of Roche HIV-1 RNA RT-PCR Monitor.